<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669149</url>
  </required_header>
  <id_info>
    <org_study_id>CHPAU 2007/01</org_study_id>
    <nct_id>NCT00669149</nct_id>
  </id_info>
  <brief_title>Anticoagulant Treatments and Percutaneous Coronary Angioplasty</brief_title>
  <acronym>TACA</acronym>
  <official_title>Anticoagulant Treatments Evaluation During Percutaneous Coronary Angioplasty in Stable Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de PAU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier de PAU</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether adjunction of intravenous anticoagulant&#xD;
      therapy (enoxaparin, HNF, bivalirudin) to antiaggregation with clopidogrel and aspirin&#xD;
      improves in-hospital results of percutaneous transluminal coronary angioplasty (ptca) in&#xD;
      selected patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Background : We don't know if using IV anticoagulant therapy is necessary for&#xD;
           percutaneous coronary angioplasty in stable patients.&#xD;
&#xD;
        -  Purpose : to compare efficacy and security of use or not of different anticoagulant&#xD;
           treatments during percutaneous coronary angioplasty in patients with double&#xD;
           antiaggregant therapy.&#xD;
&#xD;
        -  Abstract : In stable patients pretreated with double antiaggregant therapy use of IV&#xD;
           anticoagulants has not been yet evaluated during angioplasty. In this prospective&#xD;
           randomized trial we want to compare in such patients the efficacy and security of the&#xD;
           administration of IV heparin, IV enoxaparin, IV bivalirudin and no use of anticoagulant&#xD;
           during coronary angioplasty. We will evaluate in each group ischaemic events (clinic,&#xD;
           ECG and biology) and haemorrhagic events (clinic, biology) with a one month follow up.&#xD;
&#xD;
        -  Primary outcome: ischaemic events via troponin Ic measurements during 24 hours post&#xD;
           procedure.&#xD;
&#xD;
        -  Secondary outcomes: haemorrhagic events : clinical and biological evaluation (Hb, Ht,&#xD;
           TIMI score)&#xD;
&#xD;
        -  Study design : monocentric randomized clinical trial type therapeutic equivalence phase&#xD;
           IV.&#xD;
&#xD;
        -  Interventions : In patients prepared with therapeutic association (aspirin clopidogrel)&#xD;
           comparison between use or no of anticoagulant (IV heparin, IV enoxaparin or IV&#xD;
           bivalirudin).&#xD;
&#xD;
        -  Number of subjects : 120 per group (total of 480).&#xD;
&#xD;
        -  Statistical analysis : multivariate analysis with logistic regression models : each end&#xD;
           point (troponin Ic increase, haemoglobin decrease, …) will be explicated with treatment&#xD;
           group and other covariates (sex, age, creatinine, …).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment difficulties&#xD;
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 3, 2013</completion_date>
  <primary_completion_date type="Actual">August 3, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ischaemic events via troponin Ic measurements during 24 hours post procedure</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>haemorrhagic events : clinical and biological evaluation</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group without anticoagulant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group with heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group with enoxaparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group with bivalirudin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel + aspirin</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Plavix Kardégic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin + clopidogrel + aspirin</intervention_name>
    <arm_group_label>2</arm_group_label>
    <other_name>héparine Choay Plavix Kardégic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin + clopidogrel + aspirin</intervention_name>
    <arm_group_label>3</arm_group_label>
    <other_name>Lovenox Plavix Kardégic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bivalirudin + clopidogrel + aspirin</intervention_name>
    <arm_group_label>4</arm_group_label>
    <other_name>Angiox Plavix Kardégic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  stable angina pectoris or silent ischaemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  instable angina or ACS (Acute Coronary Syndrome)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas DELARCHE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de Pau</name>
      <address>
        <city>PAU</city>
        <state>Pyrénées-Atlantiques</state>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ptca</keyword>
  <keyword>antiaggregant therapy</keyword>
  <keyword>anticoagulant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

